Ioannis Avgerinos

List of Publications by Citations

15 papers	**223** citations	**7** h-index	**14** g-index
16 ext. papers	**415** ext. citations	**6.3** avg, IF	**3.49** L-index

#	Paper	IF	Citations
15	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. *Annals of Internal Medicine*, **2020**, 173, 278-286	8	70
14	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2255-2263	6.7	39
13	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2020**, 22, 335-345	6.7	27
12	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2019**, 21, 188-193	6.7	20
11	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1857-1868	6.7	14
10	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*, **2021**, 174, 108737	7.4	12
9	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2116-2124	6.7	9
8	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. *Diabetes, Obesity and Metabolism*, **2021**, 23, 822-831	6.7	6
7	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. *American Journal of Alzheimer's Disease and Other Dementias*, **2019**, 34, 281-289	2.5	5
6	Patients'and Clinicians'Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. *Journal of General Internal Medicine*, **2020**, 1	4	5
5	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2019**, 12, 2549-2557	3.4	4
4	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. *Diabetes Research and Clinical Practice*, **2021**, 177, 108921	7.4	3
3	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2022**, 24, 106-114	6.7	2
2	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2395-2401	6.7	1
1	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. *Annals of Internal Medicine*, **2021**, 174, 141	8	